Validación de percentil 99 de troponina ultrasensible obtenido en la población de un hospital general

Martínez, María Laura; Bertazzo, Brunella; Grima, Juan Gonzalez; Córdoba, Ana Virginia Figueroa; Konicoff, Mailen; Martina, Luciana; Rossa, Victoria; Amuchástegui, Marcos; Brenna, Eduardo J.; Salomone, Oscar; Guadagnoli, Adolfo Ferrero; Contreras, Alejandro

doi:10.31053/1853.0605.v77.n4.27473

Cited by 1 publication

(1 citation statement)

References 14 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only a few studies have systematically evaluated the characteristics of hs-cTnI beyond its diagnostic capabilities and out of the NSTEMI scenario [20][21][22][23][24][25]. It is worth mentioning that hs-cTnI is a more sensitive test than the standard troponin test, allowing for earlier detection of myocardial injury.…”

Section: Discussionmentioning

confidence: 99%

Clinical Implications of High-Sensitivity Troponin Elevation Levels in Non-ST-Segment Elevation Myocardial Infarction Patients: Beyond Diagnostics

Bravo,

Vizcarra,

Sánchez

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Standard troponin has long been pivotal in diagnosing coronary syndrome, especially Non-ST-Segment Elevation Myocardial Infarction (NSTEMI). The recent introduction of high-sensitivity troponin (hs-cTnI) has elevated it to the gold standard. Yet, its nuanced role in predicting angiographic lesions and clinical outcomes, notably in specific populations like obesity, remains underexplored. Aim: To evaluate the association between hs-cTnI magnitude in NSTEMI patients and angiographic findings, progression to acute heart failure, and its performance in obesity. Methods: Retrospective study of 208 NSTEMI patients at a large university center (2020–2023). Hs-cTnI values were assessed for angiographic severity, acute heart failure, and characteristics in the obese population. Data collected and diagnostic performance were evaluated using manufacturer-specified cutoffs. Results: 97.12% of patients had a single culprit vessel. Hs-cTnI elevation correlated with angiographic stenosis severity. Performance for detecting severe coronary disease was low, with no improvement using a higher cutoff. No association was found between hs-cTnI and the culprit vessel location. Hs-cTnI did not predict acute heart failure progression. In the obese population, hs-cTnI levels were higher, but acute heart failure occurred less frequently than in non-obese counterparts. Conclusions: In NSTEMI, hs-cTnI elevation is associated with significant stenosis, but not with location or acute heart failure. Obesity correlates with higher hs-cTnI levels but a reduced risk of acute heart failure during NSTEMI.

show abstract